Pharmaceutical Fraud and Whistleblower Support

Pharmaceutical fraud manifests in multiple schemes—kickbacks, off-label marketing, billing fraud, counterfeit drugs, and clinical trial manipulation—all designed to maximize profits at the expense of patients, insurers, and healthcare systems.

Whistleblowing Under the False Claims Act (Qui Tam)

Whistleblowers play a crucial role in exposing corporate wrongdoing, safeguarding patients and holding companies accountable through False Claims Act lawsuits. These complex cases require specialized legal representation.

Our team provides essential support to FCA counsel throughout the entire process—from initial case assessment through settlement negotiations. Under the qui tam provision, whistleblowers who successfully prosecute pharmaceutical fraud cases on the government’s behalf receive mandatory rewards of 15-30%, depending on case specifics.

The Department of Justice intervenes in approximately 18 to 22% of qui tam cases filed. Key factors influencing success are the following:

• Government Intervention – A successful result is more likely when the government joins the case.
• Significance of Information – The significance of the information provided by the whistleblower, the contribution of the person bringing the action, and whether the information was previously known to the government are all factors that influence the outcome.
• Prompt Reporting – Prompt reporting of the fraud is crucial because of statute of limitations. The False Claims Act features dual timing provisions: a standard six-year window from violation date and an extended ten-year period. While claims typically must be filed within six years of the violation, this deadline can stretch to ten years when government discovery of fraud is delayed—specifically when officials learn or should have learned about the violation more than three years after it occurred.